Tejal Gandhi
Research Subjects
Tejal Gandhi has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Vaishali Thakkar
Department of Pharmaceutics, Anand Pharmacy College, Anand, India
16 shared publications - Kalpana Patel
Department of Pharmaceutical Quality Assurance, Anand Pharmacy College, Anand, India
9 shared publications - Purvi Shah
Parul Institute of Pharmacy and Research, Parul University
7 shared publications Tejal G. Soni
4 shared publications- Hardik Rana
Department of Pharmaceutics, Anand Pharmacy College, Anand, India
3 shared publications - Kirti Patel
The Maharaja Sayajirao University of Baroda
3 shared publications
Latest Publications
- 27 October 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (8) , 340
NanoMiLens (Nano-Micelle Loaded Hydrogel Contact Lenses) of Tofacitinib Citrate: Amalgamation, Development, Optimization and Characterization
- 27 October 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (8) , 340
NanoMiLens (Nano-Micelle Loaded Hydrogel Contact Lenses) of Tofacitinib Citrate: Amalgamation, Development, Optimization and Characterization
- Open Access
- 26 October 2026
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 50 (1) , 129
Pediatric-friendly Smart Oro-solid Carbamazepine Dry Suspension (SOS-CDS): optimization, functionality and in-vivo taste determination
Background: Pediatric formulations are challenging to design due to considerations of convenience. Many children are suffering from an epileptic condition at an early age. Continuing anti-epileptic treatment can influence bone metabolism in children. The research was undertaken to design a pediatric and industry approachable smart stable dosage form of carbamazepine (CBZ) supplemented with Vitamin D (Vit D). Methods: Smart Oro-solid Carbamazepine Dry Suspension (SOS-CDS) was formulated using a liquorice-based suspending agent. DSC and FTIR were performed to observe interactions among CBZ, Vit D, and other excipients. Screening of various variables was performed using Failure Mode and Effects Analysis (FMEA), and the results were further optimized using a Central Composite Design (CCD) with two independent variables (suspending agent and mixing speed) and three dependent variables (sedimentation volume, blend uniformity, and %CDR). The designed SOS-CDS was evaluated for its stability and other physicochemical parameters. BATA model was utilized to assess the taste masking of carbamazepine. Results: DSC and FTIR spectra showed no interaction between the drug and excipients. QbD approach successfully optimized the SOS-CDS, identifying suspending agent concentration and mixing speed as critical variables. A total of 13 experiments were designed and evaluated. Optimized SOS-CDS showed good micromeritics properties and a desired sedimentation volume, with 93.7% release at 420 min. BATA model revealed the taste masking of CBZ. Conclusion: The major concern with the current formulation was its instability in the presence of light and moisture. The developed SOS-CDS was stable due to its intelligent mechanism. In addition, long-term use of CBZ causes bone degeneration, which may be overcome by supplementing Vitamin D. Liquorice was explored as a masking agent for the bitter taste of CBZ and was confirmed in the BATA model. The newer SOS-CDS was stable and had controlled release. The developed formulation will be useful at an industrial scale.
- 26 October 2026
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 50 (1) , 129
Open AccessPediatric-friendly Smart Oro-solid Carbamazepine Dry Suspension (SOS-CDS): optimization, functionality and in-vivo taste determination
Background: Pediatric formulations are challenging to design due to considerations of convenience. Many children are suffering from an epileptic condition at an early age. Continuing anti-epileptic treatment can influence bone metabolism in children. The research was undertaken to design a pediatric and industry approachable smart stable dosage form of carbamazepine (CBZ) supplemented with Vitamin D (Vit D). Methods: Smart Oro-solid Carbamazepine Dry Suspension (SOS-CDS) was formulated using a liquorice-based suspending agent. DSC and FTIR were performed to observe interactions among CBZ, Vit D, and other excipients. Screening of various variables was performed using Failure Mode and Effects Analysis (FMEA), and the results were further optimized using a Central Composite Design (CCD) with two independent variables (suspending agent and mixing speed) and three dependent variables (sedimentation volume, blend uniformity, and %CDR). The designed SOS-CDS was evaluated for its stability and other physicochemical parameters. BATA model was utilized to assess the taste masking of carbamazepine. Results: DSC and FTIR spectra showed no interaction between the drug and excipients. QbD approach successfully optimized the SOS-CDS, identifying suspending agent concentration and mixing speed as critical variables. A total of 13 experiments were designed and evaluated. Optimized SOS-CDS showed good micromeritics properties and a desired sedimentation volume, with 93.7% release at 420 min. BATA model revealed the taste masking of CBZ. Conclusion: The major concern with the current formulation was its instability in the presence of light and moisture. The developed SOS-CDS was stable due to its intelligent mechanism. In addition, long-term use of CBZ causes bone degeneration, which may be overcome by supplementing Vitamin D. Liquorice was explored as a masking agent for the bitter taste of CBZ and was confirmed in the BATA model. The newer SOS-CDS was stable and had controlled release. The developed formulation will be useful at an industrial scale.
- 22 October 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (8) , 330
Decoding Formulation Complexity: Comparative Performance of Statistical, Machine Learning, and Artificial Intelligence Models in Intelligent Nano Depot (iNDEP) Design
Artificial intelligence (AI) and machine learning (ML) are increasingly explored to improve predictive modelling and optimization in pharmaceutical formula
- 22 October 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (8) , 330
Decoding Formulation Complexity: Comparative Performance of Statistical, Machine Learning, and Artificial Intelligence Models in Intelligent Nano Depot (iNDEP) Design
Artificial intelligence (AI) and machine learning (ML) are increasingly explored to improve predictive modelling and optimization in pharmaceutical formula
- 18 April 2026
- Published by World Scientific Pub Co Pte Ltd in Nano LIFE
- Vol. 17 (02)
Quality by Design Approach for Formulation and Evaluation of Spray-Dried Powders Containing Nano-in-Microparticles for the Treatment of COPD
Fluticasone propionate (FP) NIMs produced with spray drying technology have been developed and assessed in vivo in this work in order to deliver the drug directly to the lungs. Using the quality by design (QbD) approach, chitosan (CS) NIMs loaded with FP have been developed by spray drying. To forecast the ultimate product quality, QbD, a modern regulatory-based quality management technique, was employed. Mannitol and leucine have been used as the deaggregating agent and to enhance aerosolization behavior, respectively. The impact of three variables, polymer content, inlet temperature and feed flow rate check, on quality parameters, such as particle size and entrapment efficiency, was determined based on risk assessment. A Box-Behnken design was applied for further optimization. The formulated compounds underwent characterization for physical attributes employing differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR) and scanning electron microscopy (SEM). Additionally, in vitro assessments, X-ray diffraction analyses and in vitro deposition evaluations were conducted utilizing a cascade impactor. In accordance with the QbD paradigm, the design space (DS) was meticulously refined through the integration of chosen variables, achieving an entrapment efficiency exceeding 50% w/w, alongside a particle size range of 800–4000 nm. The inlet temperature and polymer concentration had the greatest effects on the particle size. In vitro drug release followed initial burst release around 20.26% in 3–4 h with sustained drug release of 98.43% NIMs emitted 36–45% respirable fraction, indicating deep targeting of FP to the pulmonary. Lung histopathological studies proved the tissue compatibility of formulations to be safe and effective.
- 18 April 2026
- Published by World Scientific Pub Co Pte Ltd in Nano LIFE
- Vol. 17 (02)
Quality by Design Approach for Formulation and Evaluation of Spray-Dried Powders Containing Nano-in-Microparticles for the Treatment of COPD
Fluticasone propionate (FP) NIMs produced with spray drying technology have been developed and assessed in vivo in this work in order to deliver the drug directly to the lungs. Using the quality by design (QbD) approach, chitosan (CS) NIMs loaded with FP have been developed by spray drying. To forecast the ultimate product quality, QbD, a modern regulatory-based quality management technique, was employed. Mannitol and leucine have been used as the deaggregating agent and to enhance aerosolization behavior, respectively. The impact of three variables, polymer content, inlet temperature and feed flow rate check, on quality parameters, such as particle size and entrapment efficiency, was determined based on risk assessment. A Box-Behnken design was applied for further optimization. The formulated compounds underwent characterization for physical attributes employing differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR) and scanning electron microscopy (SEM). Additionally, in vitro assessments, X-ray diffraction analyses and in vitro deposition evaluations were conducted utilizing a cascade impactor. In accordance with the QbD paradigm, the design space (DS) was meticulously refined through the integration of chosen variables, achieving an entrapment efficiency exceeding 50% w/w, alongside a particle size range of 800–4000 nm. The inlet temperature and polymer concentration had the greatest effects on the particle size. In vitro drug release followed initial burst release around 20.26% in 3–4 h with sustained drug release of 98.43% NIMs emitted 36–45% respirable fraction, indicating deep targeting of FP to the pulmonary. Lung histopathological studies proved the tissue compatibility of formulations to be safe and effective.
- 2 November 2025
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 29 (6) , 2508-2518
Simultaneous quantification of quercetin and rifampicin in bronchoalveolar lavage fluid by HPLC-UV technique and its application to a pharmacokinetic study of investigational dry powder formulation
A rapid and precise high-performance liquid chromatography with ultraviolet detection (HPLC-UV) method has been developed for the quantitative determination of Rifampicin and Quercetin, in bronchoalveolar lavage fluid. The validation process was conducted in compliance with the USFDA guidelines. Separation was achieved using a C18-Luna Phenomenex column (5 μm, 4.60 × 150 mm) with a mobile phase comprising 20 mM disodium hydrogen orthophosphate (pH 4.5) and methanol in a 35:65 %v/v ratio. The retention times for Quercetin and Rifampicin were 5.42 and 8.60 minutes, respectively. Optimal protein precipitation was achieved using 500 μl of acetonitrile and 500 μl of methanol, yielding an extraction recovery exceeding 80 % for both drugs from bronchoalveolar lavage fluid. The extraction method yielded clean samples, rendering the process both straightforward and cost-effective. The method exhibited a strong linear correlation (r > 0.9995) between the peak area ratio and the concentrations for Rifampicin (50– 5000 ng/ml) and Quercetin (40–4000 ng/ml). Pharmacokinetic analysis revealed that poly(lactic-co-glycolic acid) nanoparticles sustained higher drug concentrations in the lung tissue for an extended period of up to 24 hours. In conclusion, the developed HPLC method, utilizing simple UV detection, offers several advantages, including costeffectiveness, high recovery rates, a broad linear range, robust quantification capability, and short analysis times.
- 2 November 2025
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 29 (6) , 2508-2518
Simultaneous quantification of quercetin and rifampicin in bronchoalveolar lavage fluid by HPLC-UV technique and its application to a pharmacokinetic study of investigational dry powder formulation
A rapid and precise high-performance liquid chromatography with ultraviolet detection (HPLC-UV) method has been developed for the quantitative determination of Rifampicin and Quercetin, in bronchoalveolar lavage fluid. The validation process was conducted in compliance with the USFDA guidelines. Separation was achieved using a C18-Luna Phenomenex column (5 μm, 4.60 × 150 mm) with a mobile phase comprising 20 mM disodium hydrogen orthophosphate (pH 4.5) and methanol in a 35:65 %v/v ratio. The retention times for Quercetin and Rifampicin were 5.42 and 8.60 minutes, respectively. Optimal protein precipitation was achieved using 500 μl of acetonitrile and 500 μl of methanol, yielding an extraction recovery exceeding 80 % for both drugs from bronchoalveolar lavage fluid. The extraction method yielded clean samples, rendering the process both straightforward and cost-effective. The method exhibited a strong linear correlation (r > 0.9995) between the peak area ratio and the concentrations for Rifampicin (50– 5000 ng/ml) and Quercetin (40–4000 ng/ml). Pharmacokinetic analysis revealed that poly(lactic-co-glycolic acid) nanoparticles sustained higher drug concentrations in the lung tissue for an extended period of up to 24 hours. In conclusion, the developed HPLC method, utilizing simple UV detection, offers several advantages, including costeffectiveness, high recovery rates, a broad linear range, robust quantification capability, and short analysis times.
- Open Access
- 3 January 2025
- Published by Taylor & Francis in Essential Chem
- Vol. 2 (1) , 1-16
DoE assisted, stability indicating HPTLC method development and validation for concurrent determination of Telmisartan and Bisoprolol fumarate in tablet dosage form
- 3 January 2025
- Published by Taylor & Francis in Essential Chem
- Vol. 2 (1) , 1-16
Open AccessDoE assisted, stability indicating HPTLC method development and validation for concurrent determination of Telmisartan and Bisoprolol fumarate in tablet dosage form
- 1 January 2021
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 16 (3) , 268-279
Design of Experiment Approach to Assess the Effect of Formulation Vari-ables on Extrusion and Spheronization of Telmisartan and Cilostazol Loaded Pellets and its Pharmacokinetic Study
Background: Solubility is an important parameter that affects the availability of drug in systemic circulation. Drugs having poor solubility belonging to BCS class II eventually result in lower dissolution and bioavailability. Hence, improvement of solubility is a challenging task. Hence the present work focuses on using solid dispersion and inclusion complex approach for both telmisartan and cilostazol belonging to BCS Class II drugs. Objective: The present study was carried out to improve apparent solubility of telmisartan and cilostazol (BCS-Class II drugs) and optimization as pellets along with its pharmacokinetic study. Methods: Phase solubility study was carried out to screen the excipients such as, PVPK30, PVA, HPMC E5 and beta-CD. Solvent evaporation method was adopted to prepare the solid dispersions and inclusion complex of both drugs. Pellets were optimized by extrusion spheronization method using 32 factorial design and characterized by morphology, drug content, DSC, FTIR, XRD, SEM, in-vitro studies and drug content study. Results: Phase solubility study showed improved apparent solubility of telmisartan with HPMC E5 ( 1:3) by solid dispersion and cilostazol with beta-CD (1:3) using inclusion complexation method. Drug characterization did not reveal any incompatibility. Formulation was optimized on the basis of acceptable pellet properties, including acceptable spherical shape and micromeritics properties. The percent friability of all batches was found to be less than 1%. The optimized pellets of both drugs prepared with micro crystalline cellulose provided desirable maximum release with acceptable release profile. Conclusion: The formulated pellets when studied in vivo showed superior pharmacokinetic profile. The drawback associated with apparent solubility and bioavailability of both drugs can thus be alleviated by use of novel pellet formulation.
- 1 January 2021
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 16 (3) , 268-279
Design of Experiment Approach to Assess the Effect of Formulation Vari-ables on Extrusion and Spheronization of Telmisartan and Cilostazol Loaded Pellets and its Pharmacokinetic Study
Background: Solubility is an important parameter that affects the availability of drug in systemic circulation. Drugs having poor solubility belonging to BCS class II eventually result in lower dissolution and bioavailability. Hence, improvement of solubility is a challenging task. Hence the present work focuses on using solid dispersion and inclusion complex approach for both telmisartan and cilostazol belonging to BCS Class II drugs. Objective: The present study was carried out to improve apparent solubility of telmisartan and cilostazol (BCS-Class II drugs) and optimization as pellets along with its pharmacokinetic study. Methods: Phase solubility study was carried out to screen the excipients such as, PVPK30, PVA, HPMC E5 and beta-CD. Solvent evaporation method was adopted to prepare the solid dispersions and inclusion complex of both drugs. Pellets were optimized by extrusion spheronization method using 32 factorial design and characterized by morphology, drug content, DSC, FTIR, XRD, SEM, in-vitro studies and drug content study. Results: Phase solubility study showed improved apparent solubility of telmisartan with HPMC E5 ( 1:3) by solid dispersion and cilostazol with beta-CD (1:3) using inclusion complexation method. Drug characterization did not reveal any incompatibility. Formulation was optimized on the basis of acceptable pellet properties, including acceptable spherical shape and micromeritics properties. The percent friability of all batches was found to be less than 1%. The optimized pellets of both drugs prepared with micro crystalline cellulose provided desirable maximum release with acceptable release profile. Conclusion: The formulated pellets when studied in vivo showed superior pharmacokinetic profile. The drawback associated with apparent solubility and bioavailability of both drugs can thus be alleviated by use of novel pellet formulation.
- 1 December 2020
- Published by ACG Publications in Journal of Chemical Metrology
- Vol. 14 (2) , 106-113
UV-spectrophotometry-assisted chemometric methods for simultaneous determination of ambroxol hydrochloride and doxofylline in pharmaceutical formulation
Two methods, ratio spectra derivative method and partial least squares regression (PLS) were developed for the simultaneous estimation of ambroxol hydrochloride and doxofylline in combined dosage form. In the first method, ratio spectra derivative method, analytical signals were measured at the wavelengths corresponding to either maximums or minimums for both drugs in the first derivative spectra of the ratio spectra obtained by dividing the standard spectrum of one of two drugs in water. Partial least squares regression (PLS) was used for data analysis of and the parameters of the chemometry procedures were optimized. In this study, the simultaneous determination of ambroxol hydrochloride and doxofylline in pharmaceuticals by chemometric approaches using UV spectrophotometry has been reported. Spectra of ABH and DOX were recorded at several concentrations within their linear ranges between 2-12 μg/mL and 15-40 μg/mL respectively and applied to pharmaceutical formulation, tablet, with no interference with excipients as indicated by the results of the recovery study. The proposed methods are simple, rapid and can be easily used in the quality control of drugs as alternative analytical tools.
- 1 December 2020
- Published by ACG Publications in Journal of Chemical Metrology
- Vol. 14 (2) , 106-113
UV-spectrophotometry-assisted chemometric methods for simultaneous determination of ambroxol hydrochloride and doxofylline in pharmaceutical formulation
Two methods, ratio spectra derivative method and partial least squares regression (PLS) were developed for the simultaneous estimation of ambroxol hydrochloride and doxofylline in combined dosage form. In the first method, ratio spectra derivative method, analytical signals were measured at the wavelengths corresponding to either maximums or minimums for both drugs in the first derivative spectra of the ratio spectra obtained by dividing the standard spectrum of one of two drugs in water. Partial least squares regression (PLS) was used for data analysis of and the parameters of the chemometry procedures were optimized. In this study, the simultaneous determination of ambroxol hydrochloride and doxofylline in pharmaceuticals by chemometric approaches using UV spectrophotometry has been reported. Spectra of ABH and DOX were recorded at several concentrations within their linear ranges between 2-12 μg/mL and 15-40 μg/mL respectively and applied to pharmaceutical formulation, tablet, with no interference with excipients as indicated by the results of the recovery study. The proposed methods are simple, rapid and can be easily used in the quality control of drugs as alternative analytical tools.
- Open Access
- 1 October 2020
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 15 (5) , 524-542
Exploring of Taguchi Design in the Optimization of Brinzolamide and Timolol Maleate Ophthalmic in-situ Gel Used in Treatment of Glaucoma
Objective: The present research work focuses on experimental design assisted In-situ gel for fixed dose combination. Significance: Brinzolamide(BZ) BCS class II drug and Timolol Maleate (TM), a BCS class I drug is formulated for obtaining the sustained effect, increased ocular bioavailability and reduction of dose leading to better patient compliance. Methods: The material attributes were gelrite, hydroxy propyl methyl cellulose K4M(HPMC K4M) and HP-β-CD and critical quality attributes identified were gel strength, mucoadhesive index and percentage of drug release of both drugs. BZ and TM were successfully formulated in ion-triggered In-situ gelling system using Taguchi design with minimum trials. Results: The final optimized formula 0.5 %w/v gelrite, 0.5 %w/v HPMC K4M, 1:2.5 Ratio of drug to HP-β-CD as well as 150rpm stirring rate exhibited acceptable results with enhanced solubility of BZ. The pharmacodynamic study revealed a decrease in intraocular pressure for In-situ gel (17.3) compared to conventional marketed suspension. Moreover, delayed mean residence time and high AUC (61.237 and 4523.65) of In-situ gel indicates prolonged residence time with sustained release. Conclusion: In conclusion, excellent ocular tolerance and longer action of gelrite and HPMC K4M. In-situ gel for BZ and TM can be explored as potential alternative to marketed formulation reducing the frequency of administration and improving patient compliance in glaucoma.
- 1 October 2020
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 15 (5) , 524-542
Open AccessExploring of Taguchi Design in the Optimization of Brinzolamide and Timolol Maleate Ophthalmic in-situ Gel Used in Treatment of Glaucoma
Objective: The present research work focuses on experimental design assisted In-situ gel for fixed dose combination. Significance: Brinzolamide(BZ) BCS class II drug and Timolol Maleate (TM), a BCS class I drug is formulated for obtaining the sustained effect, increased ocular bioavailability and reduction of dose leading to better patient compliance. Methods: The material attributes were gelrite, hydroxy propyl methyl cellulose K4M(HPMC K4M) and HP-β-CD and critical quality attributes identified were gel strength, mucoadhesive index and percentage of drug release of both drugs. BZ and TM were successfully formulated in ion-triggered In-situ gelling system using Taguchi design with minimum trials. Results: The final optimized formula 0.5 %w/v gelrite, 0.5 %w/v HPMC K4M, 1:2.5 Ratio of drug to HP-β-CD as well as 150rpm stirring rate exhibited acceptable results with enhanced solubility of BZ. The pharmacodynamic study revealed a decrease in intraocular pressure for In-situ gel (17.3) compared to conventional marketed suspension. Moreover, delayed mean residence time and high AUC (61.237 and 4523.65) of In-situ gel indicates prolonged residence time with sustained release. Conclusion: In conclusion, excellent ocular tolerance and longer action of gelrite and HPMC K4M. In-situ gel for BZ and TM can be explored as potential alternative to marketed formulation reducing the frequency of administration and improving patient compliance in glaucoma.
- 1 June 2019
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 16 (2) , 211-219
Screening of Sacrificial Excipients for Arresting Devitrification of Itraconazole from Solid Dispersion
Objectives: The aim of the present investigation was to develop a solid dispersion of itraconazole (ITR) using sacrificial excipients like pregelatinized starch and spray-dried lactose alongside hydroxypropyl methylcellulose and Poloxamer 188, thereby arresting the conversion of the amorphous form of ITR to crystalline form, and to assess the dissolution stability of an amorphous form of the drug during short-term storage. Materials and Methods: ITR-loaded solid dispersions were prepared by kneading. Formulation optimization was achieved by using a 2(4) full factorial design on the basis of cumulative percent drug released at t(30), t(60), and t(120) min. An artificial neural network (ANN) was also applied as a statistical tool for obtaining better predictive ability and the outcomes of the ANN were compared with that of Design-Expert software. Results: The spectral data revealed no drug-carrier interactions. The P-X-ray diffraction study of the optimized batch showed a decrease in the crystallinity of drug as compared to the untreated drug. The in vitro dissolution studies of the optimized batch showed higher dissolution (92% at 120 min) in comparison to the other formulations. The dissolution stability study was performed at 40 degrees C and 75% relative humidity for 90 days for the optimized formulation. The results of the optimized batch showed insignificant changes in cumulative percentage drug release during storage. Conclusion: Dissolution stability could be attributed to the presence of sacrificial excipients as they tend to absorb moisture during storage and possibly get converted into crystalline form, thereby minimizing the recrystallization of ITR.
- 1 June 2019
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 16 (2) , 211-219
Screening of Sacrificial Excipients for Arresting Devitrification of Itraconazole from Solid Dispersion
Objectives: The aim of the present investigation was to develop a solid dispersion of itraconazole (ITR) using sacrificial excipients like pregelatinized starch and spray-dried lactose alongside hydroxypropyl methylcellulose and Poloxamer 188, thereby arresting the conversion of the amorphous form of ITR to crystalline form, and to assess the dissolution stability of an amorphous form of the drug during short-term storage. Materials and Methods: ITR-loaded solid dispersions were prepared by kneading. Formulation optimization was achieved by using a 2(4) full factorial design on the basis of cumulative percent drug released at t(30), t(60), and t(120) min. An artificial neural network (ANN) was also applied as a statistical tool for obtaining better predictive ability and the outcomes of the ANN were compared with that of Design-Expert software. Results: The spectral data revealed no drug-carrier interactions. The P-X-ray diffraction study of the optimized batch showed a decrease in the crystallinity of drug as compared to the untreated drug. The in vitro dissolution studies of the optimized batch showed higher dissolution (92% at 120 min) in comparison to the other formulations. The dissolution stability study was performed at 40 degrees C and 75% relative humidity for 90 days for the optimized formulation. The results of the optimized batch showed insignificant changes in cumulative percentage drug release during storage. Conclusion: Dissolution stability could be attributed to the presence of sacrificial excipients as they tend to absorb moisture during storage and possibly get converted into crystalline form, thereby minimizing the recrystallization of ITR.